ICMJE DISCLOSURE FORM

| Date: 20 FEB 2023 | |
|--|--|
| Your Name: Philippe MERLE | |
| Manuscript Title: Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma | |
| Manuscript number (if known): | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with | Specifications/Comments | | | |
|--|---|---|---|--|--|--|
| | | whom you have this relationship or indicate | (e.g., if payments were made to you or to your institution) | | | |
| | | none (add rows as | institution) | | | |
| | | needed) | | | | |
| Time frame: Since the initial planning of the work | | | | | | |
| 1 | All support for the present | None | | | | |
| | manuscript (e.g., funding, | | | | | |
| | provision of study materials, | | | | | |
| | medical writing, article | | | | | |
| | processing charges, etc.) No time limit for this item. | | | | | |
| | No time illine for this item. | | | | | |
| | | | | | | |
| | Time frame: past 36 months | | | | | |
| 2 | Grants or contracts from | Grant | Ipsen (payment to my institution) | | | |
| | any entity (if not indicated | | | | | |
| | in item #1 above). | | | | | |
| 3 | Royalties or licenses | None | | | | |
| | | | | | | |
| 4 | Consulting food | Nana | | | | |
| 4 | Consulting fees | None | | | | |
| | | | | | | |

| 6 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | None | |
|----|--|-----------------------------------|---|
| 7 | Support for attending meetings and/or travel | Roche, AstraZeneca, MSD, Ipsen | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | Advisory Board | Roche, AstraZeneca, MSD, Eisai, Ipsen , Bayer (payment to me) |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |
| 11 | Stock or stock options | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None | |
| 13 | Other financial or non- financial interests | None | |

Please summarize the above conflict of interest in the following box:

Grant: Ipsen

Travel for meeting: Roche, Ipsen, MSD, AstraZeneca Ad Board: Roche, AstraZeneca, MSD, Eisai, Ipsen, Bayer

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.